Radioiodine dosimetry with recombinant human thyrotropin

R. Michael Tuttle, Richard J. Robbins

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations

Abstract

Although radioactive iodine (RAI) has been an essential tool in the management of thyroid cancer for more than 50 yr, there continues to be a lack of scientific rigor regarding the optimal choice of administered activity for individual patients. Often, activities of 30-150 mCi are administered for RAI remnant ablation, whereas activities ranging from 150-250 mCi are usually reserved for treatment of metastatic disease. In most cases, the activity selected is based on an empiric regimen without knowledge of the rate of RAI clearance for that individual patient.

Original languageEnglish (US)
Title of host publicationThyroid Cancer (Second Edition)
Subtitle of host publicationA Comprehensive Guide to Clinical Management
PublisherHumana Press
Pages447-451
Number of pages5
ISBN (Print)9781588294623
DOIs
StatePublished - Dec 1 2006

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Radioiodine dosimetry with recombinant human thyrotropin'. Together they form a unique fingerprint.

Cite this